S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 24 - Related articles - All 2 versions
A Karasik, P Aschner, H Katzeff, MJ Davies, … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral
antihyperglycemic agents that enhance the body's ability to regulate blood
glucose by increasing the active levels of incretins, glucagon-like peptide ... Cited by 20 - Related articles - BL Direct - All 4 versions
RE Pratley - The Medscape Journal of Medicine, 2008 - pubmedcentral.nih.gov Two classes of therapies target the incretin system. The first, glucagon-like
peptide-1 (GLP-1) agonists (exemplified by exenatide and liraglutide), have
demonstrated considerable efficacy in clinical trials, reducing hemoglobin ... Cited by 8 - Related articles - All 7 versions
B Ahrén - Expert Opin. Emerging Drugs, 2008 - informahealthcare.com Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of
glucagon-like peptide-1 (GLP-1). This increases circulating levels of active
GLP-1, stimulates insulin secretion and inhibits glucagon secretion, ... Cited by 7 - Related articles - All 8 versions
JH Wani, J John-Kalarickal, VA Fonseca - Cardiology Clinics, 2008 - Elsevier Type 2 diabetes mellitus is a metabolic disease leading to microvascular and
macrovascular complications including coronary artery disease and stroke.
Management of diabetes has been challenging, particularly in the presence ... Cited by 4 - Related articles - All 27 versions
S Halimi, A Schweizer, B Minic, J Foley, S … - Vascular Health and Risk Management, 2008 - pubmedcentral.nih.gov Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV
(DPP-4), orally active, that improves glycemic control in patients with type 2
diabetes (T2DM) primarily by enhancing pancreatic (α and β) islet ... Cited by 2 - Related articles - All 7 versions
M Banerjee, N Younis, H Soran - Expert Opinion on Pharmacotherapy, 2009 - informahealthcare.com The global rise in prevalence of diabetes, and the associated long-term
complications, will have major impact on health economies. The prevalence of
diabetes is expected to reach 220 million by 2010, with the greatest ...
JS Freeman - medscape.com Question Are the dipeptidyl peptidase-4 (DPP-4) inhibitors safe for use in
patients with renal dysfunction? ... Januvia [package insert]. Whitehouse
Station, NJ: Merck & Co, Inc; October 2008. ... Bergman AJ, Cote J, Yi B, ... Related articles - All 3 versions
R Brice - British Medical Journal, 2009 - bmj.com A 56 year old male taxi driver with a four year history of type 2 diabetes
visited the surgery because he was fed up with trying to control his blood
glucose. Although his most recent glycated haemoglobin measurement of 7.4% ... Related articles - All 2 versions
